Shionogi Announces Data Demonstrating Potent in Vitro Activity of Cefiderocol against the Most Critical Priority Gram-Negative Bacterial Pathogens
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.) and Shionogi B.V. the European subsidiary of Shionogi & Co., Ltd respectively, (hereafter “Shionogi”) today announces key data for cefiderocol, a late-stage investigational, novel siderophore cephalosporin, presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in Amsterdam, Netherlands, April 13-16, 2019. The data in these presentations suggest cefiderocol shows a high potential for treating infections caused by the most difficult to treat Gram-negative (GN) bacteria collected from across Europe, including multidrug-resistant strains.2,3
The in vitro activity of cefiderocol was evaluated against GN bacteria collected from across Europe and the activity was compared with comparator agents in a multi-national surveillance study,2 which demonstrated not only the potent activity of cefiderocol against carbapenem-resistant isolates of Enterobacteriaceae, but also against the more difficult-to-treat carbapenem-resistant non-fermentative bacteria, A. baumannii and P. aeruginosa. In this study, 99.2% of GN isolates had minimum inhibitory concentrations (MIC) of ≤4 mg/L.a
In separate studies, the susceptibility profile of cefiderocol was evaluated against a global collection of only carbapenem-resistant GN bacteria.3,4 In these studies, the in vitro activity against the European isolates and the presence of carbapenemase genes were evaluated. Cefiderocol showed antibacterial activity against 95.5% of carbapenem-resistant GN isolates at ≤4 mg/L. The study also evaluated regional differences in carbapenemase gene distribution. Significant differences were seen in carbapenemase gene profile across bacterial species between regions and especially between EU countries; yet cefiderocol showed the potential to be effective against Enterobacteriaceae, A. baumannii, and P. aeruginosa regardless of the presence of serine- and metallo-carbapenemase-encoding genes.
Similar results were seen at a national level in a study conducted in the UK, with cefiderocol demonstrating activity at low concentrations against multi-drug-resistant carbapenemase-producing P. aeruginosa and A. baumannii.5 The relevance of in vitro to clinical efficacy has yet to be determined.
“Increasing resistance in Gram-negative bacteria complicates treatment, especially where it compromises carbapenems, which are the ‘go-to’ antibiotics for difficult infections. The enzymes responsible for this resistance - carbapenemases - are diverse. Different types predominate in different countries and species, adding to the challenge,” said Professor David Livermore, Professor of Medical Microbiology, University of East Anglia.
“In the lab, cefiderocol stays active against Enterobacteriaceae with any of the common carbapenemases. What’s more it’s also active against Pseudomonas and Acinetobacter with carbapenemases. Pseudomonas is inherently difficult as most antibiotics are not effective against this critical pathogen, and Acinetobacter has unique carbapenemases that evade all the inhibitors available so far. We found cefiderocol to be almost universally active,”
Professor Livermore continued, “Overall, it’s this breadth of cefiderocol’s potential coverage against carbapenemase producers that’s so interesting. The UK doesn’t have the high prevalence of carbapenemases producers that you see in Italy, Greece, Brazil and – above all – India, but we do have diversity …. and that makes a single, widely active, agent attractive.”
John Keller, Senior Vice President Global Business Division and Head of European and US Operations Shionogi commented, “Shionogi is excited to share these important data at ECCMID, which suggests the potential activity of cefiderocol against some of the most challenging pathogens identified by the World Health Organization. Antimicrobial resistance is a major health burden and we are committed to developing effective treatments to address this growing threat.”
Notably, in addition to these results, data from several external susceptibility studies will also be presented at ECCMID, showing activity of cefiderocol against multidrug-resistant Gram-negative pathogens from Italy, Spain, Germany and the UK.
About Cefiderocol - An Investigational Antibiotic Agent
Cefiderocol is a parenteral siderophore cephalosporin with a novel mechanism for penetrating the outer cell membrane of Gram-negative pathogens including multidrug-resistant strains. Cefiderocol binds to ferric iron and is actively transported into bacterial cells through the outer membrane via the bacterial iron transporters, which function to incorporate this essential nutrient for bacteria.6 In addition, cefiderocol can also enter cells by passive diffusion through porin channels and is stable against all known classes of beta-lactamases, including both the metallo- and serine-β-lactamases.7 These mechanisms allows cefiderocol to achieve higher concentrations in the periplasmic space where it can bind to receptors and inhibit cell wall synthesis in the bacterial cells.8 Data from global surveillance studies for cefiderocol demonstrated potent in vitro activity against a wide spectrum of Gram-negative pathogens including carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacteriaceae, and Stenotrophomonas maltophilia.9 Cefiderocol has poor in vitro activity against Gram-positive or anaerobic bacteria.
Two Phase III studies are ongoing in patients with HAP/VAP/HCAP† (APEKS-NP‡) and with carbapenem-resistant pathogens at various infection sites (CREDIBLE-CR). Information is available at www.clinicaltrials.gov under the identifiers NCT02714595 and NCT03032380, respectively.
Cefiderocol is not currently commercially available.
About Gram-negative infections
The increasing resistance of many infections caused by Gram-negative bacteria to existing therapies, including carbapenem-resistant Enterobacteriaceae and non-fermenting species such as P. aeruginosa, A. baumannii, and S. maltophilia, means there is a critical need for new, effective therapies.9,10,11,12 There are an increasing number of Gram-negative pathogens resistant to multiple antibiotics, making them difficult to treat and resulting in high mortality rates.13 In the U.S., at least 2 million people are infected with antibiotic-resistant bacteria, and at least 23,000 people die as a result each year.14 In the EU, about 25 000 patients die from an infection with the selected multidrug-resistant bacteria.15 The World Health Organization have identified carbapenem-resistant strains of Enterobacteriaceae, P. aeruginosa and A. baumannii as the top priority in the research and development of new antibiotics.1
Shionogi & Co., Ltd. (“Shionogi”) is a Japanese major research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” The company currently markets products in several therapeutic areas including anti-infectives, pain, CNS disorders, cardiovascular diseases and gastroenterology. Shionogi’s research and development currently target two therapeutic areas: infectious diseases and pain/CNS disorders. For more information on Shionogi, please visit http://www.shionogi.co.jp/en/. Shionogi B.V. is the European subsidiary of Shionogi & Co., Ltd. based in Amsterdam, Netherlands. For more information on Shionogi B.V., please visit http://www.shionogi.eu/.
Forward Looking Statement
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also, for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
a The approved CLSI breakpoint for cefiderocol is defined as 4 mg/L
† Hospital-Acquired Pneumonia/Ventilator-Acquired Pneumonia/Healthcare-Associated Pneumonia.
‡ Nosocomial Pneumonia.
© 2019 Shionogi Limited. London, WC2B 6UF. All Rights Reserved.
1 World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery and development of new antibiotics. Available at: https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf Last accessed February 2019
2 ECCMID 2019. Tsuji M, et al. Cefiderocol in vitro Activity Against Gram-negative Clinical Isolates Collected in Europe: Results from 3 SIDERO-WT surveillance studies during 2014-2016
3 ECCMID 2019. Tsuji M, et al. Cefiderocol in vitro Activity Against Gram-negative Clinical Isolates Collected in Europe: Results from SIDERO-CR 2014/16
4 ECCMID 2019. Tsuji M, et al. Cefiderocol Susceptibility Profiling Against a Global Collection of Gram-negative bacteria containing Serine- and Metallo-carbapenemase genes
5 ECCMID 2019. Mushtaq S, Saduki Z, Vickers A, Livermore D. In vitro activity of cefiderocol against multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii from the UK
6 Ito A, Nishikawa T., Masumoto S, et al. Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60(12):7396-7401.
7 Tillotson GS. Trojan Horse Antibiotics—A Novel Way to Circumvent Gram-Negative Bacterial Resistance? Infectious Diseases: Research and Treatment. 2016;9:45-52 doi:10.4137/IDRT.S31567
8 Ito-Horiyama T, Ishii Y, Ito A, et al. Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases. Antimicrob Agents Chemother. 2016;60(7):4384-4386.
9 M Hackel, M Tsuji, Y Yamano, et al. n Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, Against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem Non-Susceptible Isolates: The SIDERO-WT-2014 Study. Antimicrobial Agents Chemotherapy. 2017;61(9), posted online.
10 Diene SM, Rolain JM. Carbapenemase genes and genetic platforms in gram-negative bacilli: Enterobacteriaceae, Pseudomonas and Acinetobacter species. Clin Microbiol Infect 2014; 20:831−38.
11 Livermore DM. Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med 2012; 27:128−42.
12 Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev 2012; 25:2−41.
13 Tangden T, Giske CG. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. J Intern Med 2015; 277:501−12.
14 Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in the United States 2013. Retrieved from https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf
15 European Centre for Disease Prevention and Control (ECDC). Technical Report: the bacterial challenge: time to react. 2009. Retrieved from https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf
For further information, contact:
Shionogi & Co., Ltd.
Shionogi Europe Media Contact
European Marketing Director
+44 (0) 7741 626375
Havas So Media Contact
+44 (0) 2037 933768
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Algorand Foundation Marks New Chapter in Global Economics with Inaugural Auction19.6.2019 23:56:00 EEST | Tiedote
The Algorand Foundation announced today the successful completion of its inaugural Algo auction, marking the launch of the Algorand platform and its original economic model that uses a unique combination of consensus-driven blockchain technology and economic incentives to ensure absolute fairness and broad participation in a new Borderless Economy. The auction brings Algos, the native token of the Algorand blockchain platform, into market circulation for the first time. Originally scheduled to last for more than five hours, the auction sold out in under four hours, due to oversubscribed demand from a large group of global participants. The Dutch Auction mechanism ensured the market, not the seller, set the price of the offering and that each participant paid the same price per Algo. The Algorand platform is the first public, permissionless pure proof-of-stake blockchain protocol that solves the “blockchain trilemma” of achieving scalability, security and true decentralization all at on
Cooper & Turner Announces Potential Combination with Beck Industries19.6.2019 22:32:00 EEST | Tiedote
Andaray (Holdings) Limited and its direct and indirect subsidiaries (“Cooper & Turner”) have entered into an agreement with Beck Industries (“Beck”) for potential combination of the two groups. The contemplated combined entity aims to be the first truly global manufacturer of safety critical fasteners, together supporting a broader range of industries – including renewable energy, tunneling, construction, rail, heavy equipment, downstream oil & gas, power generation and nuclear, among others. Headquartered in Sheffield, England, Cooper & Turner serves a global customer base with manufacturing and distribution operations across the European Union, China and North America. This worldwide network enables Cooper & Turner to offer a seamless, one-stop shop solution for industrial fasteners that meet the highest levels of quality. Beck, a France-based manufacturer and distributor of fully certified, high-security bolting components, has built a global operation that complements and expands t
Tinubu Square Appoints Sophie Riottot as Group Sales Director19.6.2019 20:02:00 EEST | Tiedote
Tinubu Square, a leading provider of credit insurance, surety and trade finance solutions, has announced the appointment of Sophie Riottot as Group Sales Director. This is a strategic engagement for the company, which is restructuring its sales approach to reinforce its rapid global growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005634/en/ Sophie Riottot, new Group Sales Director at Tinubu Square (Photo: Business Wire) Sophie Riottot brings a wealth of experience to Tinubu Square. She joins the company from Dhatim, a French start-up specializing in AI-powered invoice services, where she was responsible for sales strategy and partnership development. Prior to this, she was with Microsoft for over 17 years, in a variety of prominent sales and management positions, including Head of Finance in the Services Division. As a member of the executive committee at Tinubu Square, Sophie will be responsible for spearheadin
ExaGrid Voted “Enterprise Backup Hardware Product of the Year”19.6.2019 20:00:00 EEST | Tiedote
ExaGrid®, a leading provider of intelligent hyperconverged storage for backup, today announced that it has been voted Storage Magazine’s “Enterprise Backup Hardware Product of the Year” at its annual awards ceremony Storries XVI. Winners are determined by public vote, so receipt of this award is especially important; it heralds the collective voices of ExaGrid’s customers and partners, and further validates the excellence of ExaGrid’s differentiated product architecture and superior customer support model. “We’re honored to accept this award from Storage Magazine,” said Bill Andrews, President and CEO of ExaGrid. “ExaGrid’s deduplication and its scale-out architecture provides customers with a consistent backup window regardless of data growth, which is especially important in today’s ever-changing enterprise environments. The scale-out approach also eliminates forklift upgrades and forced product obsolescence. Our unique Landing Zone retains the most recent backup in its full undedupl
Luxury Pre-War Elevator Building in Prestigious Brooklyn Heights Offered for Sale19.6.2019 19:12:00 EEST | Tiedote
Holliday Fenoglio Fowler, L.P. (HFF) announces it has been selected to exclusively market the sale of 25 Monroe Place, a 12-story, 67-unit, luxury apartment building located in the Brooklyn Heights neighborhood of Brooklyn, New York. This offering provides a rare opportunity to acquire a trophy asset in the most sought-after neighborhood in Brooklyn. The vast majority of the property is comprised of fair-market units not subject to rent stabilization. 25 Monroe Place is situated in the Brooklyn Heights historic district, which provides immediate access to Manhattan, the Brooklyn Waterfront, Brooklyn Bridge Park, Downtown Brooklyn and DUMBO. Brooklyn Heights is characterized by charming brownstones and plush tree-lined streets, and the property is surrounded by medium- and low-density buildings that provide water and Manhattan skyline views. Built in 1938, 25 Monroe Place combines pre-war architectural elements and spacious apartment layouts with newly upgraded condo-quality finishes, i
Shopify Unveils New Innovations to Transform Commerce for Merchants and Consumers Globally19.6.2019 18:30:00 EEST | Tiedote
Today, Shopify Inc. (NYSE:SHOP) (TSX:SHOP), the leading multi-channel commerce platform, unveiled the latest in commerce technology at Shopify Unite, the annual conference that brings together the company’s global partner and developer community. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005550/en/ Shopify Fulfillment Network (Graphic: Business Wire) “Shopify’s real power comes from the variety and strength of our ecosystem,” said Shopify CEO Tobi Lutke. "Unite gives our developer and partner community access to our product roadmap. Together, and only together, we can shape the future of commerce and empower entrepreneurs around the world.” This year, Shopify is transforming commerce by announcing platform enhancements and updates focused on giving direct-to-consumer brands everything they need to build and manage a business. Shopify’s innovations include a newly updated Shopify Plus platform for enterprise brands
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme